Company News
Developing a first in class, once daily breakthrough treatment for cough hypersensitivity disorders.
Read the latest news
All the latest company news and events.
Professor Surinder Birring to present IPF COMFORT phase 2 study data at the 10th American Cough Conference.
Professor Surinder Birring to present IPF COMFORT phase 2 study data at the 10th American Cough Conference.
Dr Steve Pawsey, CMO at NeRRe Therapeutics to present at the 9th American Cough Conference
Dr Steve Pawsey, CMO at NeRRe Therapeutics to present at the 9th American Cough Conference
NeRRe Therapeutics raises £20 million in a Series B2 financing round
NeRRe Therapeutics raises £20 million in a Series B2 financing round
Dr Steve Pawsey, CMO at NeRRe Therapeutics to Present at The Eleventh International Cough Symposium
Dr Steve Pawsey, CMO at NeRRe Therapeutics to Present at The Eleventh International Cough Symposium
Dr Mary Kerr, CEO of NeRRe Therapeutics to present at Biotech Showcase
Dr Mary Kerr, CEO of NeRRe Therapeutics to present at Biotech Showcase
Dr Mary Kerr, CEO of NeRRe Therapeutics to Present at Biotech Showcase in San Francisco on 13 January 2020
Dr Mary Kerr, CEO of NeRRe Therapeutics to Present at Biotech Showcase in San Francisco on 13 January 2020
European Respiratory Society International Congress, Madrid 29 September 2019
European Respiratory Society International Congress, Madrid 29 September 2019
NeRRe Therapeutics Announces Publication of Positive Results in a Phase 2 Pilot Study of Orvepitant in Chronic Refractory Cough
NeRRe Therapeutics Announces Publication of Positive Results in a Phase 2 Pilot Study of Orvepitant in Chronic Refractory Cough
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough
Dr Mary Kerr CEO NeRRe Therapeutics presents at the Biotech Showcase, San Francisco
Dr Mary Kerr CEO NeRRe Therapeutics presents at the Biotech Showcase, San Francisco
Dr Mike Trower CSO KaNDy Therapeutics will be giving an invited presentation
Dr Mike Trower CSO KaNDy Therapeutics will be giving an invited presentation
Jo Craig, SVP CMC awarded Eminent Fellowship of the Academy of Pharmaceutical Sciences UK
Jo Craig, SVP CMC awarded Eminent Fellowship of the Academy of Pharmaceutical Sciences UK
Mary Kerr CEO NeRRe Therapeutics and Managing Director KaNDY Therapeutics will be presenting a case study on the “Demerger of NT-814 to KaNDY Therapeutics, Business Model Innovation and Value Creation
Mary Kerr CEO NeRRe Therapeutics and Managing Director KaNDY Therapeutics will be presenting a case study on the “Demerger of NT-814 to KaNDY Therapeutics, Business Model Innovation and Value Creation
KaNDy Therapeutics and NeRRe Therapeutics announce the appointment of Jo Craig as Head of Chemistry Manufacturing and Controls
KaNDy Therapeutics and NeRRe Therapeutics announce the appointment of Jo Craig as Head of Chemistry Manufacturing and Controls
NeRRe Therapeutics CEO, Dr Mary Kerr, nominated to present at EBD Group’s BIO-Europe Spring 2018 conference, taking place March 12–14, 2018 in Amsterdam, Netherlands
NeRRe Therapeutics CEO, Dr Mary Kerr, nominated to present at EBD Group’s BIO-Europe Spring 2018 conference, taking place March 12–14, 2018 in Amsterdam, Netherlands
9th January 2018: NeRRe Therapeutics CEO, Dr Mary Kerr, presents at the Biotech Showcase, 11:30 AM Franciscan – B (Ballroom Level), Hilton San Francisco, San Francisco, CA 94102, USA
9th January 2018: NeRRe Therapeutics CEO, Dr Mary Kerr, presents at the Biotech Showcase, 11:30 AM Franciscan – B (Ballroom Level), Hilton San Francisco, San Francisco, CA 94102, USA
Say Hello to the Top 14 Female Entrepreneurs in European Biotech
Say Hello to the Top 14 Female Entrepreneurs in European Biotech
Mary Kerr CEO NeRRe Therapeutics guest speaker at a recent Labiotech meeting in London
Mary Kerr CEO NeRRe Therapeutics guest speaker at a recent Labiotech meeting in London
KaNDy Therapeutics launched to advance a breakthrough treatment in Women’s Health
KaNDy Therapeutics launched to advance a breakthrough treatment in Women’s Health
NeRRe Therapeutics appoints Andrew Kay as Chairman of the Board
NeRRe Therapeutics appoints Andrew Kay as Chairman of the Board
NeRRe Therapeutics CEO, Dr Mary Kerr, interviewed at the 2017 Biotech Showcase by Mike Ward, Chief Content Officer at Datamonitor Healthcare & Scrip Intelligence
NeRRe Therapeutics CEO, Dr Mary Kerr, interviewed at the 2017 Biotech Showcase by Mike Ward, Chief Content Officer at Datamonitor Healthcare & Scrip Intelligence
NeRRe Therapeutics CEO, Dr Mary Kerr, will present at BioTrinity 2017, May 9th, London, UK, The title of the presentation is “NeRRe Therapeutics – a unique Neurokinin antagonist pipeline with the potential to return significant near-term value”
